VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The phase 2 study evaluated the efficacy and safety of bortezomib in combination with
lenalidomide as maintenance therapy in high risk newly diagnosed multiple myeloma patients
who receive lenalidomide,bortezomib, and dexamethasone Combination as induction therapy.